I also think it ma be due to the previous day's announcement about moving to FDA approved Phase 2 trials in the US.
We could have interest from overseas investor considering MSB owns 40% of Angioblast.
Any buying strength will move the stock quickly given there really is no-one on the sell side.
All in all, it looks very exciting.
embroyic stem cell licence, page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.005(0.52%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 98.5¢ | 91.5¢ | $4.743M | 4.999M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 123302 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |